参考文献/References:
[1] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版)[J].中华肝脏病杂志,2019,27(12):962-979.
[2] 李梦东,王宇明.实用传染病学[M].北京:人民卫生出版社,2005:405-414.
[3] Liu CH,Kao JH.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients:Optimizing use of peginterferon alfa[J].Int J Nanomedicine,2014,9:2051-2067.
[4] Udina M,Hidalgo D,Navinés R,et al.Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C:A systematic review and meta-analysis[J].J Clin Psychiatry,2014,75(10):e1113-e1121.
[5] Christensen S,Gillessen A.Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection[J].Infect Agent Cancer,2014,9(1):10.
[6] Su KP,Huang SY,Peng CY,et al.Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels[J].Biol Psychiatry,2010,67(6):550-557.
[7] Marcellin P,Lau GK,Zeuzem S,et al.Comparing the safety,tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a[J].Liver Int,2008,28(4):477-485.
[8] 刘宝咸,张燕萍,李宏燕,等.干扰素治疗慢性丙型肝炎患者致抑郁障碍的特点及干预[J].陕西医学杂志,2014,43(10):1396-1397.
[9] Chiu WC,Su YP,Su KP,et al.Recurrence of depressive disorders after interferon-induced depression[J].Transl Psychiatry,2017,7(2):e1026.
[10] Sun CF,Chiu WC,Chen PC,et al.Depression-free after interferon-α exposure indicates less incidence of depressive disorder:A longitudinal study in Taiwan[J].Brain Behav Immun,2020,88:125-131.
[11] Dieperink E,Willenbring M,Ho SB.Neuropsychiatric symptoms associated with hepatitis C and interferon alpha:A review[J].Am J Psychiatry,2000,157(6):867-876.
[12] Rowan PJ,Tabasi S,Abdul-Latif M,et al.Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C[J].J Clin Gastroenterol,2004,38(6):530-534.
[13] Leutscher PD,Lagging M,Buhl MR,et al.Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C[J].Hepatology,2010,52(2):430-435.
[14] Raison CL,Borisov AS,Broadwell SD,et al.Depression during pegylated interferon-alpha plus ribavirin therapy:Prevalence and prediction[J].J Clin Psychiatry,2005,66(1):41-48.
[15] Khalil MA,Shousha HI,El-Nahaas SM,et al.Depression in patients with chronic hepatitis-C treated with direct-acting antivirals:A real-world prospective observational study[J].J Affect Disord,2021,282:126-132.
[16] Gold PW.The organization of the stress system and its dysregulation in depressive illness[J].Mol Psychiatry,2015,20(1):32-47.
[17] Hoyo-Becerra C,Schlaak JF,Hermann DM.Insights from interferon-α-related depression for the pathogenesis of depression associated with inflammation[J].Brain Behav Immun,2014,42:222-231.
[18] Duman RS.The role of neurotrophic factors in the etiology and treatment of mood disorders[J].Neuromolecular Med,2004,5(1):11-25.
[19] Sharma AN,Costae-Silva BF,Soares JC,et al.The role of trophic factors GDNF,IGF-1 and VEGF in major depressive disorder:A comprehensive review of human studies[J].J Affect Disord,2016,197:9-20.
[20] Capuron L,Miller AH.Cytokines and psychopathology:Lessons from interferon-alpha[J].Biol Psychiatry,2004,56(11):819-824.
[21] Kenis G,Prickaerts J,Os J,et al.Depressive symptoms following interferon-α therapy:Mediated by immune-induced reductions in brain-derived neurotrophic factor? [J].Int J Neuropsychopharmacol,2011,14(2):247-253.
[22] Debnath M,Doyle KM,Langan C,et al.Recent advances in psychoneuroimmunology:Inflammation in psychiatric disorders[J].Transl Neurosci,2011,2(2):121-137.
[23] Koo JW,Russo SJ,Ferguson D,et al.Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior[J].Proc Natl Acad Sci USA,2010,107(6):2669-2674.
[24] Patas K,Penninx BW,Bus BA,et al.Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features[J].Brain Behav Immun,2014,36:71-79.
[25] Wang P,Zhu F,Konstantopoulos K.Prostaglandin E2 induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A and phosphatidylinositol 3-kinase-dependent NF-kappaB activation[J].Am J Physiol Cell Physiol,2010,298(6):1445-1456.
[26] Cesario A,Rocca B,Rutella S.The interplay between indoleamine 2,3-dioxygenase 1(IDO1)and cyclooxygenase(COX)-2 in chronic inflammation and cancer[J].Curr Med Chem,2011,18(15):2263-2271.
[27] Su KP,Lai HC,Yang HT,et al.Omega-3 fatty acids in the prevention of interferon-alpha-induced depression:Results from a randomized,controlled trial[J].Biol Psychiatry,2014,76(7):559-566.
[28] Lotrich FE,Sears B,Mcnamara RK.Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment:Relationship with interleukin-6[J].Brain Behav Immun,2013,31:48-53.
[29] Felger JC,Li L,Marvar PJ,et al.Tyrosine metabolism during interferon-alpha administration:Association with fatigue and CSF dopamine concentrations[J].Brain Behav Immun,2013,31:153-160.
[30] Hayley S,Scharf J,Anisman H.Central administration of murine interferon-α induces depressive-like behavioral,brain cytokine and neurochemical alterations in mice:A mini-review and original experiments[J].Brain Behav Immun,2013,31:115-127.
[31] Felger JC,Lotrich FE.Inflammatory cytokines in depression:Neurobiological mechanisms and therapeutic implications[J].Neuroscience,2013,246:199-229.
[32] Miller AH,Haroon E,Raison CL,et al.Cytokine targets in the brain:Impact on neurotransmitters and neurocircuits[J].Depress Anxiety,2013,30(4):297-306.
[33] Réus GZ,Jansen K,Titus S,et al.Kynurenine pathway dysfunction in the pathophysiology and treatment of depression:Evidences from animal and human studies[J].J Psychiatr Res,2015,68:316-328.
[34] Oconnor JC,Lawson MA,André C,et al.Induction of IDO by bacille calmette-guérin is responsible for development of murine depressive-like behavior[J].J Immunol,2009,182(5):3202-3212.
[35] Lin CY,Guu TW,Lai HC,et al.Somatic pain associated with initiation of interferon-alpha(IFN-α)plus ribavirin(RBV)therapy in chronic HCV patients:A prospective study[J].Brain Behav Immun Health,2020,2:100035.
[36] Su KP,Lai HC,Peng CY,et al.Interferon-alpha-induced depression:Comparisons between early- and late-onset subgroups and with patients with major depressive disorder[J].Brain Behav Immun,2019,80:512-518.
[37] Udina M,Navinés R,Egmond E,et al.Glucocorticoid receptors,brain-derived neurotrophic factor,serotonin and dopamine neurotransmission are associated with interferon-induced depression[J].Int J Neuropsychopharmacol,2016,19(4):135.
[38] Cheng SW,Li JX,Chien YC,et al.Genetic Variations of ionotropic glutamate receptor pathways on interferon-α-induced depression in patients with hepatitis C viral infection[J].Brain Behav Immun,2021,93:16-22.
[39] 王 福,苗光新,徐柏郁,等.干扰素-α致大鼠抑郁症模型制备前后血清Th1/Th2细胞因子和甲状腺激素水平的检测[J].中国老年学杂志,2019,39(3):663-665.
[40] Leff-Gelman P,Mancilla-Herrera I,Flores-Ramos M,et al.The immune system and the role of inflammation in perinatal depression[J].Neurosci Bull,2016,32(4):398-420.
[41] Miura H,Ozaki N,Sawada M,et al.A link between stress and depression:Shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression[J].Stress,2008,11(3):198-209.
[42] 刘 义,冯 慧,毛洪京,等.针刺联合西药对初发抑郁障碍患者血清5-HT及TH1/TH2的影响[J].中国针灸,2015,35(6):539-543.
[43] Wedemeyer H,Khera T,Strunz B,et al.Reversal of immunity after clearance of chronic HCV infection-all reset?[J].Front Immunol,2020,11:571166.
[44] Inserra A,Mastronardi CA,Rogers G,et al.Neuroimmunomodulation in major depressive disorder:Focus on caspase 1,inducible nitric oxide synthase,and interferon-gamma[J].Mol Neurobiol,2019,56(6):4288-4305.